Lind Kevin Robert 4

What Happened

Kevin R. Lind, a director of Avalo Therapeutics (AVTX), was granted a derivative award covering 1,370 shares on March 31, 2026. The award carries an exercise price of $12.13 per share, giving an aggregate reported value of $16,618. This was an award/grant (Form 4 code "A"), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-03-31; filing date: 2026-04-01 (timely filing).
• Instrument: Derivative (options granted) covering 1,370 shares at $12.13/share; aggregate value reported $16,618.
• Vesting: Footnote indicates the options were granted on March 31, 2026 and are 100% vested.
• Shares owned after transaction: Not disclosed in the filing.
• Transaction code: A = Award/Grant (derivative). No exercise or sale reported.

Context

This was a compensation-related grant of options that are immediately vested. No shares were sold or exercised in this filing. Awards to directors are common corporate compensation and do not, by themselves, indicate a purchase-driven bullish signal; the reported value here is relatively modest (~$16.6K).